UroMems Appoints Steffen Hovard to Chairman of the Board of Directors GRENOBLE, France, May 11, 2022 (GLOBE NEWSWIRE) --  UroMems, developer and manufacturer of UroActive™, the first active medical implantable device for treating stress urinary incontinence, today...

UroMems Completes €23 Million Series B Financing Further participation from existing investors raised additional €7 million Additional capital to fund initiation of the first clinical trial of eAUS in patients suffering from stress urinary...

UroMems Raises €16 Million to Advance Development of Electronic Artificial Urinary Sphincter (eAUS) for Stress Urinary Incontinence Capital will fund completion of preclinical studies and initiation of the first clinical trial in patients suffering from stress urinary incontinence caused by sphincter insufficiency Dr. Friedrich...

UroMems Appoints Medical Device Industry Leader Steffen Hovard to Board of Directors GRENOBLE, France, April 27, 2020 (GLOBE NEWSWIRE) -- UroMems, developer and manufacturer of its first product, the electronic artificial urinary sphincter (eAUS), for the treatment of stress urinary...

UroMems Wins Prestigious Prix Galien Med’Start-Up for Best Collaboration in the Medtech or Digital Sector NEW YORK, Oct. 25, 2019 (GLOBE NEWSWIRE) -- UroMems, developer of the eAUS electronic artificial urinary sphincter, today announced that it has received the 2019 Prix Galien USA Med’Start-Up Award...